Sunvozertinib Approved in China for NSCLC With EGFR Exon 20

The National Medical Products Administration of China has approved sunvozertinib for use in adult patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease has progressed on or following platinum-based chemotherapy.

Related Keywords

China , Peking , Beijing , Mengzhao Wang , Xiaolin Zhang , National Medical Products Administration Of China , Union Medical College Hospital , National Medical Products Administration , Peking Union Medical College Hospital , Sunvozertinib , Nsclc , Non Small Cell Lung Cancer , Lung Cancer , Exon 20 Insertion Mutations , Nmpa , Approval , Wo Konh6 Trial , Asco Annual Meeting , Egfr , Dizal ,